Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:CLYM NASDAQ:GYRE NASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.32-1.1%$4.39$1.34▼$5.15$610.33M0.761.06 million shs1.11 million shsCLYMClimb Bio$11.44+4.9%$9.87$1.16▼$12.48$624.74M0.091.09 million shs858,934 shsGYREGyre Therapeutics$5.93-2.1%$6.91$5.44▼$9.42$587.99M1.992,916 shs81,593 shsMISTMilestone Pharmaceuticals$1.27$1.65$1.00▼$3.06$158.11M0.951.18 million shs685,739 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+6.59%-7.22%-10.45%+23.45%+178.34%CLYMClimb Bio+1.02%0.00%-2.33%+55.19%+765.87%GYREGyre Therapeutics+1.92%-2.04%-16.93%-19.68%-28.15%MISTMilestone Pharmaceuticals+4.10%-1.55%-33.16%-25.29%-26.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.32-1.1%$4.39$1.34▼$5.15$610.33M0.761.06 million shs1.11 million shsCLYMClimb Bio$11.44+4.9%$9.87$1.16▼$12.48$624.74M0.091.09 million shs858,934 shsGYREGyre Therapeutics$5.93-2.1%$6.91$5.44▼$9.42$587.99M1.992,916 shs81,593 shsMISTMilestone Pharmaceuticals$1.27$1.65$1.00▼$3.06$158.11M0.951.18 million shs685,739 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+6.59%-7.22%-10.45%+23.45%+178.34%CLYMClimb Bio+1.02%0.00%-2.33%+55.19%+765.87%GYREGyre Therapeutics+1.92%-2.04%-16.93%-19.68%-28.15%MISTMilestone Pharmaceuticals+4.10%-1.55%-33.16%-25.29%-26.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50167.13% UpsideCLYMClimb Bio 3.07Buy$21.7390.72% UpsideGYREGyre Therapeutics 2.00Hold$17.00186.20% UpsideMISTMilestone Pharmaceuticals 2.50Moderate Buy$7.25468.63% UpsideCurrent Analyst Ratings BreakdownLatest MIST, GYRE, ACRS, and CLYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/15/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/14/2026MISTMilestone Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$8.00 ➝ $7.005/12/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M76.79N/AN/A$0.85 per share5.06CLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/AGYREGyre Therapeutics$116.59M4.94$0.22 per share26.78$1.48 per share4.01MISTMilestone Pharmaceuticals$1.55M102.41N/AN/A$0.39 per share3.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)CLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)GYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)MISTMilestone Pharmaceuticals-$63.06M-$0.68N/AN/AN/AN/A-339.33%-61.79%8/12/2026 (Estimated)Latest MIST, GYRE, ACRS, and CLYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026MISTMilestone Pharmaceuticals$0.06-$0.20-$0.26-$0.20$30.12 million$0.24 million5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/A3/20/2026Q4 2025MISTMilestone Pharmaceuticals-$0.18-$0.16+$0.02-$0.15$37.52 million$1.55 million3/12/2026Q4 2025GYREGyre Therapeutics$0.08$0.04-$0.04-$0.02$36.30 million$37.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03CLYMClimb BioN/A27.8627.86GYREGyre TherapeuticsN/A4.644.06MISTMilestone Pharmaceuticals1.619.189.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CLYMClimb Bio69.76%GYREGyre Therapeutics23.99%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%CLYMClimb Bio2.60%GYREGyre Therapeutics9.50%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableCLYMClimb Bio957.26 million55.77 millionN/AGYREGyre Therapeutics4097.03 million87.81 millionNo DataMISTMilestone Pharmaceuticals30124.50 million100.22 millionOptionableMIST, GYRE, ACRS, and CLYM HeadlinesRecent News About These CompaniesMilestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks TranscriptJune 10 at 2:01 PM | seekingalpha.comMilestone Pharmaceuticals: Here Comes The Revenue RampJune 9 at 4:03 PM | seekingalpha.comMilestone Pharmaceuticals: Taking The Long ViewJune 5, 2026 | seekingalpha.comMilestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2026 | finance.yahoo.comWhy Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 8.42%May 14, 2026 | aaii.comAWells Fargo & Company Issues Pessimistic Forecast for Milestone Pharmaceuticals (NASDAQ:MIST) Stock PriceMay 14, 2026 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comMilestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 14, 2026 | globenewswire.comMilestone Pharmaceuticals (NASDAQ:MIST) Issues Earnings ResultsMay 13, 2026 | marketbeat.comMilestone Pharmaceuticals Q1 Earnings Call HighlightsMay 13, 2026 | marketbeat.comMilestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comMilestone Reports Q1 Results, Highlights Initial CARDAMYST SalesMay 13, 2026 | benzinga.comMilestone Reports Q1 Results, Highlights Initial CARDAMYST SalesMay 13, 2026 | benzinga.comMilestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue EstimatesMay 13, 2026 | zacks.comMilestone Pharmaceuticals Reports Progress on CARDAMYST™ Launch and Financial Performance for Q1 2026May 13, 2026 | quiverquant.comQMilestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comMilestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026May 6, 2026 | globenewswire.comInsider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells 36,500 Shares of StockApril 21, 2026 | insidertrades.comMilestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTApril 10, 2026 | globenewswire.comMilestone's nasal spray heart drug available via Express ScriptsApril 7, 2026 | ncbiotech.orgNMilestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Zscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityBy Thomas Hughes | May 27, 2026MIST, GYRE, ACRS, and CLYM Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.32 -0.05 (-1.14%) Closing price 04:00 PM EasternExtended Trading$4.32 +0.00 (+0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Climb Bio NASDAQ:CLYM$11.44 +0.53 (+4.86%) Closing price 04:00 PM EasternExtended Trading$11.35 -0.09 (-0.79%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Gyre Therapeutics NASDAQ:GYRE$5.93 -0.13 (-2.15%) Closing price 04:00 PM EasternExtended Trading$5.95 +0.02 (+0.34%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Milestone Pharmaceuticals NASDAQ:MIST$1.27 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.01 (+1.18%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
